Skip to content
Peptigraph home

LL-37 Dosage: Doses Studied, Units and Chart

What doses of LL-37 have been used in published research, how they convert to syringe units, and what is still unknown.

Medically reviewed by Juan Pablo Frías, MD · · DisclosureAntimicrobial peptideUpdated
Doses studied
4 studies
with a stated dose, listed below
Frequency
twice weekly
as used in studies
Half-life
Not found
No published half-life found (PubMed search, 11 Oct 2026)

Doses used in published studies

Each dose below is quoted from a study abstract, strongest design first. Animal doses are labelled and do not translate directly to people. None of them is a recommendation.

Doses of LL-37 used in published studies
DoseFrequency and routeStudy typeSource
Recombinant LL-37 Lactococcus lactis (oral LL-37)oralHuman RCTn = 238Journal of medical virology 2023, PMID 37605995
0.5 or 1.6 mg/mLtopical, with compression therapyHuman RCTn = 148Wound repair and regeneration 2021, PMID 34687253
0.5, 1.6 or 3.2 mg/mLtwice weekly · topical application to ulcer · 4 weeks randomized treatmentHuman RCTn = 34Wound repair and regeneration 2014, PMID 25041740
20 ug LL-37under the ulcer bedAnimal · mouse (not a human result)n = 6Military Medical Research 2020, PMID 32321591

Before anyone considers it

  • LL-37 is not FDA approved for any use.
  • Products sold as research chemicals are not checked by the FDA for identity, purity or dose.
  • Reconstitution math (mg vs mcg, units vs mL) is the most asked question in peptide forums. Check every number twice.
  • People who are pregnant, breastfeeding, or have a chronic condition need medical advice first.

Topical concentrations, not injected doses

The first-in-man LL-37 trial applied it to venous leg ulcers twice weekly at 0.5, 1.6 or 3.2 mg/mL during a 4-week treatment phase.[5]

The two lower strengths cut mean ulcer area by 68% (0.5 mg/mL) and 50% (1.6 mg/mL), while the 3.2 mg/mL group showed no healing difference from placebo.[5]

A later trial compared LL-37 at 0.5 or 1.6 mg/mL with a placebo cohort.[4]

Result at the lower strengths in the larger trial

In the full study population there was no significant healing improvement over placebo. The benefit appeared only in a post hoc subgroup with wounds of at least 10 cm2.[4]

Drugs@FDA lists no LL-37 product, so no label sets an amount.[18]

Common questions

Is LL-37 FDA approved?

No. LL-37 is not FDA approved for any use. The FDA removed it from Category 2 on 15 Apr 2026.

What is the LL-37 peptide dosage in trials?

Trials applied topical concentrations of 0.5, 1.6 or 3.2 mg/mL twice weekly for 4 weeks to leg ulcers. These were not injected doses.[5]

Is there an LL-37 dosage chart?

No. The only strengths sourced are the topical ones tested in ulcer trials, and Drugs@FDA lists no product.[18]

More on LL-37

Sources

  1. 1Certain bulk drug substances for use in compounding that may present significant safety risks (Category 2; 'nominated but withdrawn' table, content current as of 22 Apr 2026)U.S. Food and Drug Administration · 2026fda.govAccessed 2 Oct 2026
  2. 2Metric (SI) Prefixes (NIST Reference on Constants, Units, and Uncertainty)National Institute of Standards and Technology (NIST) · 2025physics.nist.govAccessed 2 Oct 2026
  3. 3BASAGLAR (insulin glargine) injection, prescribing information (DailyMed)U.S. Food and Drug Administration / DailyMed (Eli Lilly and Company label) · 2026dailymed.nlm.nih.govAccessed 2 Oct 2026
  4. 4Evaluation of LL-37 in healing of hard-to-heal venous leg ulcers: A multicentric prospective randomized placebo-controlled clinical trial.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2021PMID 34687253Accessed 2 Oct 2026
  5. 5Treatment with LL-37 is safe and effective in enhancing healing of hard-to-heal venous leg ulcers: a randomized, placebo-controlled clinical trial.Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society · 2014PMID 25041740Accessed 2 Oct 2026
  6. 6Chitosan hydrogel encapsulated with LL-37 peptide promotes deep tissue injury healing in a mouse model.Military Medical Research · 2020PMID 32321591Accessed 2 Oct 2026
  7. 7PubMed search: "LL-37"[tiab] OR LL37[tiab] (3020 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  8. 8PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (randomized[tiab] OR clinical trial[pt] OR patients[tiab]) (730 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  9. 9PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (ulcer*[tiab] OR wound[tiab]) (261 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  10. 10PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (venous[tiab] AND ulcer*[tiab]) (7 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  11. 11PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (healed[tiab] OR healing[tiab]) AND (randomized[tiab] OR placebo[tiab]) (4 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  12. 12PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (half-life[tiab] OR pharmacokinetic*[tiab] OR stability[tiab]) (136 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  13. 13PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (infection[tiab] OR antimicrobial[tiab] OR biofilm[tiab]) AND (mice[tiab] OR rat[tiab] OR murine[tiab]) (386 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 2 Oct 2026
  14. 14Efficacy and safety of Oral LL-37 against the Omicron BA.5.1.3 variant of SARS-COV-2: A randomized trial.Journal of medical virology · 2023PMID 37605995Accessed 11 Oct 2026
  15. 15PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (adverse[tiab] OR "side effect*"[tiab] OR safety[tiab] OR tolerab*[tiab] OR toxicity[tiab]) AND (trial[tiab] OR patients[tiab] OR topical[tiab] OR clinical[tiab]) (87 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  16. 16PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (topical[tiab] OR cream[tiab] OR ulcer*[tiab] OR "phase"[tiab] OR volunteers[tiab]) AND (adverse[tiab] OR safety[tiab] OR tolerab*[tiab] OR irritation[tiab]) (18 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  17. 17PubMed search: ("LL-37"[tiab] OR LL37[tiab]) AND (melanoma[tiab] OR intratumoral[tiab] OR intra-tumoral[tiab]) (21 results)PubMed · 2026pubmed.ncbi.nlm.nih.govAccessed 11 Oct 2026
  18. 18Drugs@FDA (openFDA) search: active ingredient "LL-37"U.S. Food and Drug Administration · 2026api.fda.govAccessed 2 Oct 2026

Found an error? Report a correction.